Leadership & Pay ·
Karyopharm Therapeutics Inc. implemented a 2026 Leadership Cash Retention Program to incentivize key employees during…
KPTIKaryopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. implemented a 2026 Leadership Cash Retention Program to incentivize key employees during upcoming meaningful catalysts. The program replaces previously guaranteed 2026 Annual Bonus Plan amounts, providing lump sum cash retention awards to CEO Richard Paulson ($1,725,000), EVP Chief Development Officer Stuart Poulton ($640,000), Dr. Reshma Rangwala ($725,000), and CFO Lori Macomber ($625,000). Karyopharm Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing small molecule therapeutics for cancer and related diseases.